In a report sent to clients this morning, Nephron MedTech analyst Chris Pasquale took a closer look at the relationship between weight and OSA and quantified the potential exposure sleep device makers like Inspire Medical and ResMed could face as GLP-1 use ramps
Clinical studies indicate that this medication can facilitate a significant reduction in body mass, with participants achieving an average decrease of 15% in body mass over 68 weeks
Clinical data suggests Retatrutide may result in greater total fat loss due to its glucagon receptor activation
Medicines made from this hormone, known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), were originally designed to help those with type 2 diabetes to manage their blood glucose levels 2
Plaintiffs contend that manufacturers knew or should have known about the association between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION), yet omitted this critical information from drug labels and prescribing materials
Novo Nordisk then followed with the launch of NovoCare Pharmacy in March 2025, enabling eligible self-pay patients to receive Wegovy (semaglutide) via direct home delivery at a reduced cash price